A Food and Drug Administration (FDA) advisory panel gave a half-hearted recommendation to expand the indication of the type 2 diabetes drug Jardiance (empagliflozin) to include prevention of cardiovascular events, and raised important questions involving a key study used to make those claims. Since 2008, developers of approved type 2 diabetes drugs are required to collect data to rule out an increase in cardiovascular risk. Such was the case with Jardiance, which was approved in August 2014. But developer Boehringer Ingelheim opted to take its EMPA-REG study a step forward, using a broader sample of patients with type 2 diabetes and an ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.